MedTrace Logo

Palliative Care Population Management Project for Integrated Care Management Program for High-Risk Patients

NCT02879357 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 194

Last updated 2019-10-11

No results posted yet for this study

Summary

The hypothesis of the Serious Illness Care Program (SICP) is that adherence to the Serious Illness Conversation Guide (SICG) portion, the SIGC, will enhance patient understanding and allow control over their own decisions, relieve burdens of decision-making on family members, and help patients achieve a state of peace as they approach the end of life.

Conditions

  • Failure to Thrive

Interventions

BEHAVIORAL

Training

1. Clinician training 2. System for patient selection 3. System of "triggering" and tracking conversations 4. Training on how to use the Serious Illness Care Guide, a guide for patients about initiating conversations with family members about end-of-life goals and values 5. Longitudinal Medical Record (LMR) documentation module to serve as a "Single source of truth" about advance care preferences in the LMR.

Sponsors & Collaborators

  • Partners HealthCare

    collaborator OTHER

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Rachelle E Bernacki, MD · Dana-Farber Cancer Institute

  • Susan D Block, MD · Dana-Farber Cancer Institute

  • Rebecca Cunningham, MD · Brigham and Women's Hospital

  • Joshua R Lakin, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02879357 on ClinicalTrials.gov